SALT LAKE CITY, Jan. 31, 2013 (GLOBE NEWSWIRE) -- In the fourth calendar quarter (4Q) 2012 and year of 2012, Utah Medical Products, Inc.'s (Nasdaq:UTMD) changes in financial results compared to the same time period in the prior calendar year were as follows:
|4Q (October – December)||Year (January – December)|
|Earnings Per Share:||+19%||+35%|
Earnings per share for the 2012 calendar year were $2.74. Excluding the noncash effects of depreciation, amortization of intangible assets and non-cash stock option expense and asset impairment expense, 2012 consolidated earnings before taxes plus interest expense were $18,703. Currency amounts throughout this report are in thousands, except per share amounts and where noted.
Profitability measures compared to the same time periods in the prior calendar year were as follows:
|Gross Profit Margin (GPM):||61.2%||59.7%||60.9%||59.2%|
|Operating Profit Margin (OPM):||36.3%||29.4%||36.6%||31.3%|
|Net Profit Margin (NPM):||23.0%||18.8%||24.5%||19.6%|
"UTMD obviously had an outstanding financial year in 2012 in a difficult economic environment for medical device companies, particularly in the U.S. After acquiring Femcare Holdings Limited in March 2011, UTMD was able to achieve profit margins more typical of its long term historical performance by realizing operating synergies from the combination of the entities. In 2013, UTMD will have the additional burden of the Obamacare medical device excise tax, which will be 2.3% of finished medical device sales in the U.S. If the excise tax were applied to 2012 revenues, it would have reduced net profits by about $210, reducing eps 6 cents per share. By achieving additional operating efficiencies, obtaining the benefit of a further lowered corporate income tax rate in the UK and continuing to focus our resources in more growth-oriented environments outside the U.S. where the tax is not applicable, UTMD hopes to mitigate the negative impact of the new tax on shareholder value in 2013.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts